{"id":"tau-284","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL3654045","moleculeType":"Small molecule","molecularWeight":"935.54"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Tau-284 works by binding to tau protein and preventing its aggregation, which is associated with neurodegenerative diseases such as Alzheimer's disease.","oneSentence":"Tau-284 is a tau aggregation inhibitor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:31.498Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Alzheimer's disease"}]},"trialDetails":[{"nctId":"NCT01840605","phase":"PHASE3","title":"A Confirmatory Study of TAU-284 in Pediatric Patients With Atopic Dermatitis","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2013-03","conditions":"Dermatitis, Atopic","enrollment":303},{"nctId":"NCT01861522","phase":"PHASE3","title":"The Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2013-04","conditions":"Perennial Allergic Rhinitis","enrollment":473},{"nctId":"NCT01425632","phase":"PHASE3","title":"A Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2011-08","conditions":"Perennial Allergic Rhinitis","enrollment":490},{"nctId":"NCT01900054","phase":"PHASE3","title":"A Long-Term Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2013-06","conditions":"Perennial Allergic Rhinitis","enrollment":58},{"nctId":"NCT04693429","phase":"PHASE1","title":"Clinical Study for the Evaluation of Safety and Tolerability of PRO-172 Ophthalmic Solution+","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2020-09-24","conditions":"Safety, Tolerability, Ocular Surface","enrollment":22},{"nctId":"NCT04877678","phase":"PHASE4","title":"Effects of Second-generation Antihistamine Bepotastine on Cough Outcomes in Cough Patients With Allergic Rhinitis","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2021-10-01","conditions":"Allergic Rhinitis, Cough","enrollment":50},{"nctId":"NCT04776096","phase":"PHASE4","title":"Efficacy and Toxicity of Bepotastine 1,5% PF vs Olopatadine 0,2% With BAK on Allergic Conjunctivitis Treatment","status":"COMPLETED","sponsor":"Laboratorios Poen","startDate":"2021-03-10","conditions":"Allergic Conjunctivitis","enrollment":97},{"nctId":"NCT01277341","phase":"PHASE2","title":"Safety and Efficacy of Bepotastine Besilate Nasal Spray in the Treatment of Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2010-12","conditions":"Seasonal Allergic Rhinitis","enrollment":601},{"nctId":"NCT01578278","phase":"PHASE2","title":"Bepotastine Besilate-corticosteroid Nasal Spray Combination Compared to Placebo, Bepotastine Besilate Nasal Spray, and Corticosteroid Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2011-12","conditions":"Seasonal Allergic Rhinitis","enrollment":606},{"nctId":"NCT01753739","phase":"PHASE2","title":"Bepotastine Besilate Nasal Sprays in the Treatment of Seasonal Allergic Rhinitis (SAR)","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2013-01","conditions":"Seasonal Allergic Rhinitis","enrollment":617},{"nctId":"NCT01222299","phase":"PHASE1, PHASE2","title":"Safety, Pharmacokinetics, and Efficacy of Bepotastine Besilate Nasal Product After Ragweed Pollen Exposure in an Environmental Chamber","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2010-05","conditions":"Seasonal Allergic Rhinitis","enrollment":89},{"nctId":"NCT01174823","phase":"PHASE2","title":"Safety and Efficacy of Bepotastine Besilate Ophthalmic Solution in Seasonal Allergic Conjunctivitis Patients","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2010-06","conditions":"Allergic Conjunctivitis","enrollment":245},{"nctId":"NCT01346371","phase":"PHASE4","title":"The Effect of BEPREVE 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer","status":"COMPLETED","sponsor":"Minnesota Eye Consultants, P.A.","startDate":"2011-05","conditions":"Allergic Conjunctivitis","enrollment":40},{"nctId":"NCT03932435","phase":"NA","title":"Bioequivalence Test of \"Dong-a Bepotastine Besilate Tab\" and \"Twolion Tab\"","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2019-04-23","conditions":"Healthy","enrollment":32},{"nctId":"NCT04097951","phase":"PHASE1","title":"HDDO-1801 Intervention Trial","status":"UNKNOWN","sponsor":"Hyundai Pharmaceutical Co., LTD.","startDate":"2019-11-08","conditions":"Respiratory Disease","enrollment":36},{"nctId":"NCT01443442","phase":"PHASE4","title":"Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Southern California College of Optometry at Marshall B. Ketchum University","startDate":"2011-10","conditions":"Allergic Conjunctivitis","enrollment":23},{"nctId":"NCT01339507","phase":"","title":"A Patient Reported Ocular Comfort Assessment Comparing Bepreve to Lastacaft","status":"COMPLETED","sponsor":"Cunningham, Derek N., O.D., P.A.","startDate":"2011-04","conditions":"Allergic Conjunctivitis","enrollment":25},{"nctId":"NCT02332044","phase":"PHASE1","title":"Drug Interaction Study Between Erdosteine and Bepotastine Besilate in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2014-04","conditions":"Healthy","enrollment":36},{"nctId":"NCT01450176","phase":"NA","title":"Comparing Patient Satisfaction With Pataday or Bepreve","status":"COMPLETED","sponsor":"McCabe Vision Center","startDate":"2011-09","conditions":"Eye Allergies","enrollment":30},{"nctId":"NCT01925313","phase":"PHASE1","title":"A Randomized, Open Label, Three-Treatment, Three-Period, Six-Sequence Crossover Study To Compare Safety and Pharmacokinetic Properties of CJ-30044 and Bepotastine Besilate and To Investigate Food-effect on Pharmacokinetics of CJ-30044 in Healthy Adult Male Volunteers","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2012-12","conditions":"Healthy","enrollment":30},{"nctId":"NCT01897428","phase":"PHASE1","title":"PK Comparisons of Bepotastine Besilate 10 mg and Bepotastine Salicylate 9.64 mg","status":"COMPLETED","sponsor":"Korea University Anam Hospital","startDate":"2011-04","conditions":"Allergic Rhinitis, Urticaria, Pruritus","enrollment":26},{"nctId":"NCT00424398","phase":"PHASE2, PHASE3","title":"Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2007-02","conditions":"Conjunctivitis, Allergic","enrollment":107},{"nctId":"NCT00586625","phase":"PHASE3","title":"Safety Study for Bepotastine Besilate Ophthalmic Solution in Normal Volunteers","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2007-10","conditions":"Allergic Conjunctivitis","enrollment":861},{"nctId":"NCT00586664","phase":"PHASE3","title":"Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2007-10","conditions":"Allergic Conjunctivitis","enrollment":130},{"nctId":"NCT01337557","phase":"PHASE4","title":"Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses","status":"UNKNOWN","sponsor":"Hom, Milton M., OD, FAAO","startDate":"2011-05","conditions":"Allergic Conjunctivitis","enrollment":24},{"nctId":"NCT01128556","phase":"PHASE4","title":"The Evaluation of Bepreve on the Measurement of Wheal and Flare Response From Histamine Skin Prick Testing","status":"COMPLETED","sponsor":"North Texas Institute for Clinical Trials","startDate":"2010-04","conditions":"Histamine Responsive Allergy Patients","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TAU-284","genericName":"TAU-284","companyName":"Tanabe Pharma Corporation","companyId":"tanabe-pharma-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bepotastine besilate ophthalmic solution is being studied for its safety, tolerability, and effectiveness in treating acute allergic conjunctivitis. The study, NCT00424398, is evaluating the onset and duration of action of bepotastine besilate in comparison to a placebo.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}